



## Emerging Trends in Gastrointestinal Tract Disease Therapies

Guest Editors:

**Dr. Puo-Hsien Le**

Department of Gastroenterology  
and Hepatology, Chang Gung  
Memorial Hospital, Linkou  
Branch, Taoyuan 333, Taiwan

**Dr. Jenwei Chou**

Division of Gastroenterology and  
Hepatology, Department of  
Internal Medicine, China Medical  
University Hospital, Taichung  
404327, Taiwan

**Dr. Chen-Shuan Chung**

Division of Gastroenterology and  
Hepatology, Department of  
Internal Medicine, Far Eastern  
Memorial Hospital, New Taipei  
City, Taiwan

Deadline for manuscript  
submissions:

**30 September 2024**

### Message from the Guest Editors

Dear Colleagues,

In an era marked by unparalleled advancements in gastrointestinal (GI) tract disease therapies, this Special Issue is poised to capture and illuminate the significant progress characterizing this vibrant field. Our mission is to highlight the most recent trends, cutting-edge treatments, and transformative research shaping the future of GI disease management. We cordially invite submissions of original research and in-depth reviews. Our focus encompasses:

- Innovative therapeutic approaches—exploration of the latest pharmacological advancements, including biologics, small molecules, gene therapies, and their transformative impact on inflammatory bowel disease and other autoimmune-related GI disorders;
- Endoscopic breakthroughs—advancements in minimally invasive techniques, encompassing endoscopic bariatric therapy, endoscopic anti-reflux therapy, natural orifice transluminal endoscopic surgery, and more, and their efficacy in GI treatment;
- Gut microbiome research—insightful perspectives on the therapeutic roles of gut microbiota in GI diseases, unveiling novel interventions;



[mdpi.com/si/195094](https://mdpi.com/si/195094)

Dr. Puo-Hsien Le

Dr. Jenwei Chou

Dr. Chen-Shuan Chung

Guest Editors

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)